Sarad Baral, MD
Internal Medicine · Pocomoke City, MDNPI 1497713283
Payments from drug & device makers
Across 133 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$291
- AstraZeneca$232
- AbbVie$165
- Boehringer Ingelheim$164
- Pfizer$157
- Novartis$139
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,13796%
- Education$1014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 17 | $291 |
| AstraZeneca | 15 | $232 |
| AbbVie(2 entities) | 8 | $165 |
| Boehringer Ingelheim | 11 | $164 |
| Pfizer | 11 | $157 |
| Novartis | 8 | $139 |
| Astellas Pharma US Inc | 5 | $130 |
| Sunovion Pharmaceuticals Inc. | 9 | $124 |
| Bayer | 6 | $114 |
| Novo Nordisk | 7 | $103 |
| Exact Sciences | 5 | $100 |
| GSK | 6 | $100 |
| Neurocrine Biosciences, Inc. | 3 | $62 |
| Amgen | 3 | $48 |
| Ardelyx, Inc. | 2 | $33 |
| Lundbeck LLC | 2 | $30 |
| Merck | 2 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $25 |
| Johnson & Johnson | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Medtronic | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,238 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 662 | $295,578 |
| TrulicityDulaglutide | 111 | $87,349 |
| NuplazidPimavanserin Tartrate | 34 | $82,491 |
| OzempicSemaglutide | 61 | $75,309 |
| XareltoRivaroxaban | 142 | $74,009 |
| MounjaroTirzepatide | 45 | $58,042 |
| JardianceEmpagliflozin | 95 | $47,948 |
| JanuviaSitagliptin Phosphate | 99 | $38,726 |
| Breo ElliptaFluticasone/Vilanterol | 95 | $37,227 |
| TradjentaLinagliptin | 47 | $31,562 |
| Spiriva RespimatTiotropium Bromide | 59 | $31,052 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $29,151 |
| GlatopaGlatiramer Acetate | 23 | $28,989 |
| TivicayDolutegravir Sodium | 12 | $28,638 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 82 | $26,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $157 | $295,578662 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $291 | $145,391156 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $164 | $110,562201 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arexvy, Incruse Ellipta | $100 | $101,474246 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $20 | $86,363159 claims |
| Acadia Pharmaceuticals IncNuplazid | $14 | $82,49134 claims |
| Novo NordiskOzempic | $103 | $75,30961 claims |
| MerckJanuvia, Lagevrio (Eua), Janumet Xr | $25 | $70,615132 claims |
| NovartisEntresto | $139 | $25,46744 claims |
| AstraZenecaFarxiga | $232 | $25,14557 claims |
| AmgenProlia | $48 | $19,51011 claims |
| AbbVieLinzess | $165 | $19,19034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Pocomoke City
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.